These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34161631)

  • 1. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.
    Jabbour E; Patel K; Jain N; Duose D; Luthra R; Short NJ; Zugmaier G; San Lucas A; Velasco K; Tran Q; Zaman F; Konopleva M; Kantarjian H
    Am J Hematol; 2021 Oct; 96(10):E379-E383. PubMed ID: 34161631
    [No Abstract]   [Full Text] [Related]  

  • 2. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
    Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
    Kawakami Y; Imamura M; Imai C
    Int J Hematol; 2024 May; 119(5):479-480. PubMed ID: 38492197
    [No Abstract]   [Full Text] [Related]  

  • 5. The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia.
    Wu X; Lu S; Zhang X; Yang Z; Sun A; Wu D; Zhou H; Miao M
    Cancer Med; 2024 Sep; 13(17):e70161. PubMed ID: 39240182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
    Couturier MA; Thomas X; Raffoux E; Huguet F; Berthon C; Simand C; Gallego-Hernanz MP; Hicheri Y; Hunault Berger M; Saillard C; Leguay T; Loiseau C; Béné MC; Chevallier P
    Leuk Lymphoma; 2021 Mar; 62(3):620-629. PubMed ID: 33153370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
    Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
    [No Abstract]   [Full Text] [Related]  

  • 8. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
    Heraudet L; Galtier J; Favre S; Peyraud F; Cazaubiel T; Leroy H; Mottal N; Gros FX; Forcade E; Clément L; Dumas PY; Pigneux A; Leguay T
    Br J Haematol; 2022 Aug; 198(3):523-527. PubMed ID: 35524489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Kobayashi Y; Oh I; Miyamoto T; Lee WS; Iida H; Minami H; Maeda Y; Jang JH; Yoon SS; Yeh SP; Tran Q; Morris J; Franklin J; Kiyoi H
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):311-318. PubMed ID: 34185953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
    Marini BL; Sun Y; Burke PW; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome.
    Rav ES; Wahba A; Patnaik A; Toruner G; Hittle A; Toepfer L; Roth M; Cuglievan B; Nunez C; McCall D
    Pediatr Blood Cancer; 2023 May; 70(5):e30191. PubMed ID: 36602024
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
    Sutton R; Pozza LD; Khaw SL; Fraser C; Revesz T; Chamberlain J; Mitchell R; Trahair TN; Bateman CM; Venn NC; Law T; Ong E; Heatley SL; McClure BJ; Meyer C; Marschalek R; Henderson MJ; Cross S; White DL; Kotecha RS
    Pediatr Blood Cancer; 2021 May; 68(5):e28922. PubMed ID: 33638292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extramedullary relapse of
    Aldoss I; Song JY
    Blood; 2018 May; 131(22):2507. PubMed ID: 29853461
    [No Abstract]   [Full Text] [Related]  

  • 20. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.